PTPRN2 and breast carcinoma: Furthermore, increased expression of both PTPRN2 and PLCB1 associated with significantly worse overall survival (Fig 1G) and worse distal metastasis‐free survival (Fig 1H) in two large breast cancer patient cohorts (Gyorffy et al, 2010; Cancer Genome Atlas Network, 2012).